📢 𝐓𝐡𝐞 𝐯𝐞𝐫𝐲 𝐟𝐢𝐫𝐬𝐭 𝐉𝐀𝐏𝐂𝐌 𝐧𝐞𝐰𝐬𝐥𝐞𝐭𝐭𝐞𝐫 𝐢𝐬 𝐡𝐞𝐫𝐞! Inside, you’ll discover: 🔹 Key highlights and milestones from the first six months 🔹 Editorial insights from the three JA PCM ARMS 🔹 The first results and achievements of the project 📖 Read the newsletter here: tinyurl.com/2v2db9dt

📣 𝐒𝐢𝐠𝐧-𝐮𝐩 𝐭𝐨 𝐭𝐡𝐞 𝐉𝐀 𝐏𝐂𝐌 𝐧𝐞𝐰𝐬𝐥𝐞𝐭𝐭𝐞𝐫 Do you want to stay up to date and connected with all activities and events happening within JA PCM? From updates and insights to opportunities you will not want to miss, the JA PCM newsletter will keep you in the loop. 👉 Sign-up here: tinyurl.com/ycd7mmfu

The Joint Action on Personalised Cancer Medicine (JA PCM) is opening the door to private sector engagement! We are pleased to invite you to the upcoming webinar: 𝐏𝐫𝐢𝐯𝐚𝐭𝐞 𝐒𝐞𝐜𝐭𝐨𝐫 𝐄𝐧𝐠𝐚𝐠𝐞𝐦𝐞𝐧𝐭: 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 & 𝐍𝐞𝐱𝐭 𝐒𝐭𝐞𝐩𝐬 📅 26 May 2026 🕒 13:00 – 15:00 (CEST) www.linkedin.com/events/74584...

📄 EFPIA has published a Precision Oncology White Paper outlining actions to improve access to personalised cancer care in Europe. JA PCM is proud to be recognised in the paper as a driver in providing Member States with a framework to integrate PCM! 🔗 Find the paper here: tinyurl.com/5xd8c8xy

Across Europe, cancer care is evolving - and JA PCM will help lead the way! 🌍 With 𝟭𝟰𝟱 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬 𝐮𝐧𝐢𝐭𝐞𝐝 𝐢𝐧 𝐨𝐧𝐞 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐉𝐨𝐢𝐧𝐭 𝐀𝐜𝐭𝐢𝐨𝐧, JA PCM is strengthening the PCM network across Europe. 🔎 Curious to learn more about our ambitious European Joint Action? Take a look: zenodo.org/records/1842...

🚀 We took part in the kick-off meeting of the @japcm.bsky.social: a new EU initiative to expand access to personalised cancer care across Europe. 🔬 As partners, VHIO lead a pilot to create a supranational Molecular Tumor Board for rare and complex cases and work on harmonising data collection.

We’re excited to kick off the Joint Action on Personalised Cancer Medicine (JA PCM) today in Brussels 🎉 Funded by #EU4Health, 146 organisations from 29 European countries are joining forces to advance personalised cancer care across the full patient pathway, from prevention to follow-up.